4427-29-6

Usage

InChI:InChI=1/C3H9NO/c1-3(2)5-4/h3H,4H2,1-2H3

Downstream Products

• 69956-41-8 3-hydroxy-N-isopropoxy-2,2-diphenyl-propionamide 
• 252872-64-3 N-isopropoxy-4-methoxybenzenesulfonamide 
• 918144-03-3 N-(4-nitrophenoxycarbonyl)isopropoxylamine 
• 1262232-56-3 (Z)-4-hydroxy-3-((E)-1-(isopropoxyimino)ethyl)-5-(4-methoxybenzylidene)-1,5-dihydro-2H-pyrrole-2-one 
• 1262232-61-0 (Z)-5-(2-chlorobenzylidene)-4-hydroxy-3-((E)-1-(isopropoxyimino)ethyl)-1,5-dihydro-2H-pyrrole-2-one 
• 1262232-67-6 (Z)-5-(4-chlorobenzylidene)-4-hydroxy-3-((E)-1-(isopropoxyimino)ethyl)-1,5-dihydro-2H-pyrrole-2-one 
• 1262232-47-2 (Z)-5-benzylidene-4-hydroxy-3-((E)-1-(isopropoxyimino)ethyl)-1,5-dihydro-2H-pyrrole-2-one 
• 212630-57-4 3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-N-isopropoxy-benzamide 
• 108898-78-8 O-Isopropyl-phenyl-acetonoxim 
• 38128-92-6 3-Formylrifamycin SV O-i-Propyloxim 
• 59373-25-0 2-(1-Isopropoxyamino-butylidene)-5,5-dimethyl-cyclohexane-1,3-dione 

Relevant academic research and scientific papers

Cyclocarbamate derivatives as progesterone receptor modulators

This invention provides compounds of Formula (I): wherein R1 and R2 may be single substituents or fused to form spirocyclic or hetero-spirocyclic rings; R3 is H, OH, NH2, C1 to C6 alkyl, substituted C1 to C6 alkyl, C3 to C6 alkenyl, substituted C1 to C6 alkenyl, alkynyl, or substituted alkynyl, CORC; RC is H, C1 to C3 alkyl, substituted C1 to C3 alkyl, aryl, substituted aryl, C1 to C3 alkoxy, substituted C1 to C3 alkoxy, C1 to C3 aminoalkyl, or substituted C1 to C3 aminoalkyl; R4 is H, halogen, CN, NO2, C1 to C6 alkyl, substituted C1 to C6 alkyl, alkynyl, or substituted alkynyl, C1 to C6 alkoxy, substituted C1 to C6 alkoxy, amino, C1 to C6 aminoalkyl, or substituted C1 to C6 aminoalkyl; and R5 is selected from a trisubstituted benzene ring of a five or six membered ring with 1, 2, or 3 heteroatoms from the group including O, S, SO, SO2 or NR6 and containing one or two independent substituents from the group including H, halogen, CN, NO2, amino, and C1 to C3 alky, C1 to C3 alkoxy, C1 to C3 aminoalkyl, CORF, or NRGCORF; or pharmaceutically acceptable salt thereof, as well as pharmaceutical compositions and methods using the compounds as antagonists of the progesterone receptor.

Cyclothiocarbamate derivatives as progesterone receptor modulators

The present invention provides compounds which are agonists of the progesterone receptor and have the structures: wherein R1and R2are independent substituents selected from the group of H, optionally substituted C1to C6alkyl, alkenyl, alkynyl, or alkynyl groups C3to C8cycloalkyl, aryl, substituted aryl, or heterocyclic groups, or CORAor NRBCORA; or R1and R2are fused to form an optionally substituted 3 to 8 membered Spiro cyclic alkyl or alkenyl ring or a Spiro cyclic ring containing one to three heteroatoms selected from O, S and N; RAis selected from H, amino, or optionally substituted C1to C3alkyl, aryl, C1to C3alkoxy, or C1to C3aminoalkyl groups; RBis H, C1to C3alkyl, or substituted C1to C3alkyl; R3is H, OH, NH2, CORC, or optionally substituted C1to C6alkyl, C3to C6alkenyl, or alkynyl groups; RCis selected from H or optionally substituted C1to C3alkyl, aryl, C1to C3alkoxy, or C1to C3aminoalkyl groups; Q1is S, NR7, or CR8R9; R5is an optionally trisubstituted benzene ring or an optionally substituted five or six membered heterocyclic ring with 1, 2, or 3 ring heteroatoms selected from the group of O, S, SO, SO2or NR6; or a pharmaceutically acceptable salt thereof, as well as methods of using these compounds for contraception and the treatment of progesterone-related maladies.

Combination regimens using progesterone receptor modulators

This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having the general structure: wherein R1and R2may be single substituents or fused to form spirocyclic or hetero-spirocyclic rings; R3is H, OH, NH2, C1to C6alkyl, substituted C1to C6allyl C3to C6alkenyl, substituted C1to C6alkenyl, alkynyl, or substituted alknyl, CORC; RCis H, C1to C3alkyl, substituted C1to C3alkyl, aryl, substituted aryl, C1to C3alkoxy, substituted C1to C3alkoxy, C1to C3aminoalkyl, or substituted C1to C3aminoalkyl; R4is H, halogen, CN, NO2, C1to C6alkyl, substituted C1to C6alkyl alkynyl, or substituted alkynyl, C1to C6alkoxy, substituted C1to C6alkoxy, amino, C1to C6aminoalkyl, or substituted C1to C6aminoalkyl; and R5is selected from a trisubstituted benzene ring of a five or six membered ring with 1, 2, or 3 heteroatoms from the group including O, S, SO, SO2or NR6and containing one or two independent substituents from the group including H, halogen, CN, NO2, amino, and C1to C3alkyl, C1to C3alkoxy, C1to C3aminoalkyl, CORF, or NRGCORF; or pharmaceutically acceptable salt thereof. These methods of treatment may be used for contraception or for the treatment and/or prevention of secondary amenorrhea, dysfunctional bleeding, uterine leiomyomata, endometriosis; polycystic ovary syndrome, carcinomas and adenocarcinomas of the endometrium, ovary, breast, colon, prostate, or inmization of side effects or cyclic menstrual bleeding. Additional uses of the invention include stimulation of food intake.